Bermekimab

Bermekimab (MABp1) is a human monoclonal antibody targeting interleukin-1α (IL-1α) . Bermekimab can prevent tumor-related inflammation. Bermekimab can be used in the research of atopic dermatitis[1].

Product Specifications

CAS Number

[1401965-15-8]

Product Name Alternative

MABp1

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bermekimab.html

Purity

97.68

Solubility

10 mM in DMSO

Smiles

[Bermekimab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]McDonald JJ, et, al. Targeting IL-1α in cancer cachexia: a narrative review. Curr Opin Support Palliat Care. 2018 Dec;12 (4) :453-459.|[2]Gong J, et al. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Nov 4;12 (1) :18731.|[3]O'Sullivan Coyne G, et al. MABp1 for the treatment of colorectal cancer. Expert Opin Biol Ther. 2017 Sep;17 (9) :1155-1161.